TRAVERSA SERGIO (Chief Executive Officer) purchased 69.4% of their position (100K shares) of RELMADA THERAPEUTICS, INC. on the open market
Open‑market purchase worth $386.7K — a major conviction buy. The strongest form of insider conviction signal.
P · 3 purchases
Filed: 1/31/2024ACC: 0001213900-24-008560
DirectorOfficer· Chief Executive Officer
Since Dec 2018
+100K
Net shares
Net buyer
$386.7K
Total acquired
3
Open market trades
3B · 0S
3
Total transactions
100K acquired
Non-Derivative Transactions3
Common Stock
Direct
Shares
+31.54K
Price / share
$3.71
Trade value
$117.04K
% of position
21.9%
1/29/2024
144.02K→175.56K
Common Stock
Direct
Shares
+41K
Price / share
$3.90
Trade value
$159.95K
% of position
23.4%
1/30/2024
175.56K→216.56K
Common Stock
Direct
Shares
+27.46K
Price / share
$4.00
Trade value
$109.75K
% of position
12.7%
1/31/2024
216.56K→244.02K
Total
Net shares
+100K
Net value
$386.74K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 1/29/2024 | P · Purchase | +31.54K | $3.71 | $117.04K | 21.9% | 144.02K | 175.56K |
| Common Stock Direct | 1/30/2024 | P · Purchase | +41K | $3.90 | $159.95K | 23.4% | 175.56K | 216.56K |
| Common Stock Direct | 1/31/2024 | P · Purchase | +27.46K | $4.00 | $109.75K | 12.7% | 216.56K | 244.02K |
| Total | +100K | $386.74K | ||||||
Derivative Transactions0
No derivative transactions reported